Marion Webb
Managing Editor at Medtech Insight
Managing Editor, Citeline, dog mom, runner, recovering triathlete. All views are my own. #medtech #digitalhealth #robotics #AI #ML #femtech #womenshealth
Articles
-
6 days ago |
insights.citeline.com | Marion Webb
Precision Neuroscience’s FDA Clearance For Core Component Of Brain Implant Expected to Accelerate R&DPrecision’s recent FDA clearance for a core part of its next-generation wireless brain-computer interface system opens the pathway to a safer, more humane BCI for researchers to use compared to higher-risk intracortical arrays, according to BCI expert Naveen Rao.
-
1 week ago |
insights.citeline.com | Marion Webb
Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff UncertaintiesAbbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.
-
1 week ago |
insights.citeline.com | Marion Webb
MedStar Teams Up With Reimagine Care To Extend Cancer Care Into Patients’ Home Reimagine Care teamed up with MedStar Health to support cancer patients at home via an AI assistant and clinical support. Reimagine Care’s data suggests its platform can save cancer centers up to $1m annually per full-time oncologist panel and reduce ED visits by 30%.
-
2 weeks ago |
insights.citeline.com | Marion Webb
LSI 2025: Vektor Medical CEO Says ‘Arrhythmia Is The Biggest Health Care Crisis Nobody Talks About,’ vMap Treats It With 91.1% AccuracyVektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.
-
2 weeks ago |
insights.citeline.com | Marion Webb
Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle LibreDexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 3K
- DMs Open
- No
Dexcom’s FDA Warning Letter Shows Risks Of Driving Margin As Firm Aims To Launch 15-Day Sensor https://t.co/17BMcyL7RL @Medtech_Insight #medtech #diabetes #FDA @IrmaRaste @EvanKirstel
‘Preparing For Regulatory Milestones, Commercial Launch’ Are Priorities, Says New Freenome CEO Aaron Elliott https://t.co/0cUae0jo4N #medtech @Medtech_Insight @IrmaRaste @EvanKirstel #cancer #colorectal_cancer #liquidbiopsy
LSI 2025: Egg Medical Builds ‘Nests’ Around Interventional Cardiologists To Protect Against Scatter Radiation https://t.co/eYER3Uxcbn @Medtech_Insight @Citeline @IrmaRaste @EvanKirstel #radiology #cardiology #AI #interventionalcardiology #radiation #healthcare